Innate Pharma S.A. ADS - ADR Peer Comparison
$1.60
$-0.10
(-5.88%)
As on 29-Sep-2026 16:00EDT
Market cap
$190 Mln
Revenue (TTM)
$66 Mln
P/E Ratio
--
P/B Ratio
20.1
Div. Yield
0 %
Edit
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
190 | 1,862 | 1,696 | 796 | 582 |
Revenue (€ Mln) |
3 | 1,044 | 30 | 4 | 144 |
Net Profit (€ Mln) |
-49.18 | 488.78 | -23.96 | -340.16 | -158.17 |
Net Margin (%) |
-72.76 | 46.83 | -- | -540.52 | -110.21 |
RoE (%) |
764.76 | 15.95 | 31.91 | 501.41 | -168.93 |
Price to Earnings |
-- | 3.18 | -- | -- | -- |
Price-To-Book |
20.10 | 0.49 | 65.02 | 2.10 | 6.47 |
Income Statement (€ Mln)
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2.79 | 1,112.25 | 29.64 | 4.48 | 174.66 |
|
Cost of Revenue
|
-- | 29.74 | -- | 2.80 | 107.14 |
|
Gross Profit
|
2.79 | 1,082.51 | 29.64 | 1.51 | 67.52 |
|
Operating Expenses
|
56.21 | 581.12 | 40.46 | 137.37 | 149.15 |
|
Operating Profit (EBIT)
|
-53.43 | 501.39 | -10.82 | -130.95 | -81.63 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-49.18 | 300.87 | -23.96 | -342.33 | -114.12 |
|
Provision for Tax
|
-5.96 | -18.62 | 0.00 | 0.02 | 1.07 |
|
Profit after Tax (Net Income)
|
-49.18 | 320.88 | -23.96 | -340.16 | -115.19 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities (€ Mln)
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-21.69 | 3,234.49 | -84.48 | -29.04 | 106.17 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
47.75 | 17.78 | 94.74 | 200.57 | 199.33 |
|
Current Liabilities
|
36.63 | 152.80 | 57.51 | 77.35 | 93.33 |
|
Total Liabilities
|
62.69 | 3,405.07 | 67.76 | 248.88 | 398.84 |
Assets (€ Mln)
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
16.00 | 326.92 | 5.01 | 5.04 | 176.30 |
|
Current Assets
|
46.69 | 3,078.15 | 62.75 | 243.84 | 222.54 |
|
Total Assets
|
62.69 | 3,405.07 | 67.76 | 248.88 | 398.84 |
|
Total Debt*
|
22.56 | 6.92 | 95.32 | 59.40 | 207.25 |
|
Net Current Assets
|
10.06 | 2,926.59 | 5.24 | 167.09 | 129.21 |
Cashflow (€ Mln)
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-32.56 | -189.23 | -33.42 | -100.98 | -52.89 |
|
Cash Flow from Investing Activities
|
20.63 | 219.35 | -0.58 | -127.93 | -1.71 |
|
Cash from Financing Activities
|
-1.97 | -3.14 | 37.42 | 232.00 | -0.62 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-241.67 | 10.44 | 1,208.63 | 3,098.72 | -32.40 |
|
ROE (%)
|
764.76 | 10.47 | 31.91 | 501.41 | -80.16 |
|
ROA (%)
|
-56.61 | 8.51 | -35.45 | -184.95 | -25.63 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-1,764.51 | 28.85 | -80.83 | -7,587.80 | -65.95 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.78 | 3.04 | 5.12 | -0.51 | 0.03 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
0.59 | 333.15 | 64.83 | -84.66 | -840.57 |
|
EPS Growth (%)
|
0.12 | 3.39 | 0.65 | 0.85 | -6.62 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-3.25 | 6.71 | -46.14 | -8.71 | -6.64 |
|
Price / Book Value
|
-7.37 | 0.67 | -13.09 | -102.03 | 7.20 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-3.40 | -2.33 | -95.14 | -21.78 | -17.09 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.04 | 0.00 | -1.13 | -2.05 | 1.95 |
|
Short term debt to equity ratio
|
-0.41 | 0.00 | -0.05 | -1.11 | 0.19 |
|
Current Ratio
|
1.27 | 20.15 | 1.09 | 3.15 | 2.38 |
|
Quick Ratio
|
-- | 20.00 | -- | 3.15 | 1.85 |
|
Interest Coverage
|
-110.77 | 136.71 | -1.30 | -4.05 | -1.72 |
Operating Efficiency Ratios
| Innate Pharma S.A. ADS - ADR | Galapagos NV - ADR | Nanobiotix (NBTX) | Inventiva Sa (IVA) | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
273.05 | 4.78 | 25.91 | 203.37 | 15.92 |
|
Asset Turnover
|
0.03 | 0.29 | 0.44 | 0.02 | 0.39 |
|
Receivable days
|
606.33 | 16.53 | 99.90 | 866.65 | 65.89 |
|
Inventory Days
|
-- | 452.54 | -- | 0.00 | 177.10 |
|
Payable days
|
-- | 1,242.94 | -- | 3,844.90 | 37.01 |
|
Cash Conversion Cycle
|
-- | -773.87 | -- | -2,978.25 | 205.98 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
